SCHEMBL5545156

SCHEMBL5545156

CCCCCCOC(=O)NCC

nearest known ligand 0.71

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ACHE P22303 14/20 0.71
EPHX1 P07099 1/20 0.68
NAAA Q02083 1/20 0.55
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10813916 1.00 ACHE (0.71) ACHEEPHX1NAAANPC1RAB9A
SCHEMBL11493296 1.00 ACHE (0.71) ACHEEPHX1NAAANPC1RAB9A
SCHEMBL28075463 1.00 ACHE (0.71) ACHEEPHX1NAAANPC1RAB9A
SCHEMBL5546852 0.98 ACHE (0.68) ACHEEPHX1NAAANPC1RAB9A
SCHEMBL10812054 0.94 ACHE (0.67) ACHEEPHX1
SCHEMBL970930 0.91 ACHE (0.64) ACHEEPHX1
SCHEMBL16673943 0.91 ACHE (0.63) ACHEEPHX1
SCHEMBL28167774 0.91 ACHE (0.61) ACHEEPHX1NAAANPC1RAB9A
SCHEMBL5243992 0.87 ACHE (0.71) ACHEEPHX1
SCHEMBL11597788 0.86 ACHE (0.58) ACHEEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
WO-2021252640-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES, INC. (US) 2021-12-16 WO disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
WO-2002000622-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 WO disclosed
EP-0397167-A2 Method of forming images FUJI PHOTO FILM CO., LTD. (JP) 1990-11-14 EP disclosed
EP-0311110-A2 Direct positive color photographic materials FUJI PHOTO FILM CO., LTD. (JP) 1989-04-12 EP disclosed
US-4146550-A REACTION OF CARBAMIC ACID CHLORIDE WITH ACTIVE HYDROGEN COMPOUND, DECOMPOSITION BAYER AKTIENGESELLSCHAFT (DE) 1979-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ACHE 4670/4885EPHX1 4071/4885NAAA 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.